Literature DB >> 29655448

Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology.

Michael K Hehir1, Nicholas J Silvestri2.   

Abstract

Myasthenia gravis (MG) is a rare disease, but the most common disorder of the neuromuscular junction. It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles. The majority of patients with MG first present with ocular symptoms. Most patients with MG will experience at least 1 exacerbation of symptoms throughout the course of their illness. This article will cover the epidemiology, clinical presentation, classification, and natural history of MG.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylcholine receptor; Antimuscle-specific kinase; Myasthenia gravis; Occular

Mesh:

Year:  2018        PMID: 29655448     DOI: 10.1016/j.ncl.2018.01.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  23 in total

1.  Frailties and critical issues in neuromuscular diseases highlighted by SARS-CoV-2 pandemic: how many patients are still "invisible"?

Authors:  Giulia Ricci; Francesca Torri; Francesca Bianchi; Lorenzo Fontanelli; Erika Schirinzi; Elisa Gualdani; Paolo Francesconi; Delia Gagliardi; Gigliola Serra; Tiziana Mongini; Gabriele Siciliano
Journal:  Acta Myol       Date:  2022-03-31

Review 2.  The relationship between myasthenia gravis and COVID-19: a systematic review.

Authors:  Dodik Tugasworo; Aditya Kurnianto; Yovita Andhitara; Rahmi Ardhini; Jethro Budiman
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2022-07-07

3.  Systems Pharmacology and Molecular Docking Reveals the Mechanisms of Nux Vomica for the Prevention of Myasthenia Gravis.

Authors:  Chao Qiu; Qiang Chen; Qun Hou; Guanshu Qi
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-26       Impact factor: 2.650

4.  Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases.

Authors:  Dao-Ping Sun; Wen-Ming Chen; Li Wang; Zhen Wang; Jin-Hua Liang; Hua-Yuan Zhu; Lei Fan; Yu-Jie Wu; Wei Xu; Jian-Yong Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

5.  Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.

Authors:  Rui Zhao; Ying Wang; Xiao Huan; Huahua Zhong; Zhirui Zhou; Jianying Xi; Yuwei Da; Lin Lei; Ting Chang; Zhe Ruan; Lijun Luo; Shengnan Li; Huan Yang; Yi Li; Sushan Luo; Chongbo Zhao
Journal:  J Transl Med       Date:  2021-06-30       Impact factor: 5.531

Review 6.  Recent advances in understanding and managing myasthenia gravis.

Authors:  Allison Jordan; Miriam Freimer
Journal:  F1000Res       Date:  2018-10-31

Review 7.  Receptor autoimmunity: diagnostic and therapeutic implications.

Authors:  Renato Tozzoli
Journal:  Auto Immun Highlights       Date:  2020-01-07

8.  A Case of COVID-19 Vaccine Causing a Myasthenia Gravis Crisis.

Authors:  Ariana R Tagliaferri; Spandana Narvaneni; Moh'd Hazem Azzam; William Grist
Journal:  Cureus       Date:  2021-06-10

9.  Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.

Authors:  James F Howard; Chafic Karam; Marcus Yountz; Fanny L O'Brien; Tahseen Mozaffar
Journal:  Ann Clin Transl Neurol       Date:  2021-05-27       Impact factor: 4.511

10.  Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States.

Authors:  Linda Harris; Phillip H Allman; Reinee Sheffield; Gary Cutter
Journal:  J Clin Neuromuscul Dis       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.